Immunotech Biopharm Ltd
HKEX:6978.HK
1.6 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 28.155 | 0 | 24.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | -28.155 | 0 | -24.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0.046 | 0.046 | 0.052 | 0.052 | 0.037 | 0.037 | 0.038 | 0.038 | 0.05 | 0.05 | 0.067 | 0.067 | 0.054 | 0.054 | 0.092 | 0.092 | 0.047 | 0.047 | 0.019 | 0.019 | 0.012 | 0.012 |
| General & Administrative Expenses
| 0.012 | 0.012 | 0.014 | 0.014 | 0.013 | 0.013 | 0.026 | 0.026 | 0.023 | 0.023 | 0.031 | 0.031 | 0.021 | 0.021 | 0.021 | 0.021 | 0.014 | 0.014 | 0.008 | 0.008 | 0.006 | 0.006 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 23.304 | 0 | 48.194 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 0.012 | 0.012 | 0.014 | 0.014 | 0.013 | 0.013 | 0.026 | 0.026 | 0.023 | 0.023 | 0.031 | 0.031 | 0.021 | 0.021 | 0.021 | 0.021 | 0.014 | 0.014 | 0.008 | 0.008 | 0.006 | 0.006 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 0.057 | 0.057 | 0.066 | 0.107 | 0.058 | 0.058 | 0.088 | 0.088 | 0.071 | 0.071 | 0.104 | 0.104 | 0.075 | 0.075 | 0.134 | 0.134 | 0.087 | 0.087 | 0.029 | 0.029 | 0.025 | 0.025 |
| Operating Income
| -0.057 | -0.057 | -0.066 | -0.066 | -0.05 | -0.05 | -0.064 | -0.064 | -0.074 | -0.074 | -0.098 | -0.098 | -0.075 | -0.075 | -0.113 | -0.113 | -0.061 | -0.061 | -0.027 | -0.027 | -0.022 | -0.022 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.011 | 0.011 | -0.043 | -0.043 | -0.01 | -0.01 | -0.026 | -0.026 | 0.002 | 0.002 | -0.006 | -0.006 | 0.001 | 0.001 | -0.02 | -0.02 | -0.026 | -0.026 | -0.002 | -0.002 | -0.007 | -0.007 |
| Income Before Tax
| -0.046 | -0.046 | -0.108 | -0.108 | -0.059 | -0.059 | -0.089 | -0.089 | -0.071 | -0.071 | -0.104 | -0.104 | -0.074 | -0.074 | -0.133 | -0.133 | -0.087 | -0.087 | -0.029 | -0.029 | -0.025 | -0.025 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0 | -0 | -0 | -0.552 | -0 | -1.252 | -0.001 | -0.001 | -0.001 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net Income
| -0.046 | -0.046 | -0.108 | -0.108 | -0.059 | -0.059 | -0.089 | -0.089 | -0.07 | -0.07 | -0.103 | -0.103 | -0.074 | -0.074 | -0.133 | -0.133 | -0.087 | -0.087 | -0.029 | -0.029 | -0.025 | -0.025 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0 | -0.09 | -0.21 | -0.21 | -0.12 | -0.12 | -0.18 | -0.18 | -0.14 | -0.14 | -0.2 | -0.2 | -0.15 | -0.15 | -0.26 | -0.26 | -0.23 | -0.23 | -0.08 | -0.08 | -0.067 | -0.067 |
| EPS Diluted
| -0 | -0.09 | -0.21 | -0.21 | -0.11 | -0.11 | -0.17 | -0.17 | -0.14 | -0.14 | -0.2 | -0.2 | -0.14 | -0.14 | -0.26 | -0.26 | -0.23 | -0.23 | -0.077 | -0.077 | -0.067 | -0.067 |
| EBITDA
| -0.042 | -0.042 | -0.053 | -0.053 | -0.037 | -0.037 | -0.054 | -0.054 | -0.062 | -0.062 | -0.092 | -0.092 | -0.07 | -0.07 | -0.109 | -0.11 | -0.058 | -0.058 | -0.024 | -0.027 | -0.021 | -0.021 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |